Trial Profile
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs BLD-2660 (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Acronyms BLADE-CONQUER
- Sponsors Blade Therapeutics
- 01 Apr 2022 Status changed from active, no longer recruiting to completed.
- 22 Feb 2021 Planned End Date changed from 30 Nov 2020 to 1 Nov 2021.
- 13 Oct 2020 Planned End Date changed from 1 Oct 2020 to 30 Nov 2020.